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Anaplastic large cell lymphoma (ALCL) is rare, accounting for 10e15% of all childhood non-Hodgkin’s
lymphomas. We present a case of primary isolated ALCL in the lung of a 5-year-old boy. An asymptomatic
5-year-old boy had absent breath sounds over his right hemithorax on routine physical exam. Chest X-ray
showed complete white-out of the right hemithorax. Chest CT scan demonstrated a mass occluding the
right mainstem bronchus. The ﬁrst bronchoscopic biopsy was reported as an endobronchial neoplasm
with an immunophenotype consistent with Ewing’s sarcoma/PNET. One week later, a repeat second
bronchoscopy with re-biopsy conﬁrmed the correct diagnosis of ALCL, null phenotype. Clinical and
radiological staging revealed no evidence of extrathoracic disease in the past, present, or for three-
months after presentation, conﬁrming isolated primary endobronchial ALCL. Complete remission at
6-months with polychemotherapy was achieved. Although a rare tumor of the lung, ALCL should be
considered in the differential diagnosis of ‘unusual lung neoplasms’ in children.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Non-Hodgkin’s lymphoma (NHL) of the lung encompasses 3.6%
of extranodal lymphomas, and only 0.3% of primary lung neo-
plasms [1]. These tumors may be classiﬁed into two types: a) Type
1: submucosal inﬁltrates originating from hematogenous or lym-
phangitic spread in the presence of systemic lymphoma, or b)
Type 2: adjacent airway involvement by a localized mass due to
direct spread from adjacent lymph nodes [2]. Pediatric non-
Hodgkin’s lymphoma most commonly affects the lymph nodes
and may be associated with mediastinal involvement and hep-
atosplenomegaly, with extranodal sites of involvement including
the skin, bone, muscle, and lung parenchyma [3].
Anaplastic large cell lymphoma (ALCL), representing 10e15%
of pediatric lymphomas, occurs most commonly in children
and young adults with a bimodal age distribution [2]. ALCL
most commonly affects the sinusoids of lymph nodes, and is
often associated with involvement of the mediastinum and hep-
atosplenomegaly. Extranodal ALCL may involve the skin, boneartment of Pathology & Lab-
ital Drive, Saskatoon, SK S7N
on.ca (R. Kanthan).
Inc. Open access under CC BY-NC-ND marrow, soft tissue, pelvis, central nervous system, bone, gastro-
intestinal tract, lung, pleura, breast, chest wall, retroperitoneum,
and spleen [3]. When ALCL involves the lung, it is most commonly
the result of advanced disseminated disease. Dissemination is
hypothesized to occur via direct invasion from adjacent medias-
tinal or parenchymal disease, or by lymphatic spread, and/or
hematogenous spread. Primary isolated endobronchial ALCL in the
pediatric population is exceedingly rare, with very few reports in
the published English literature.
We herein report the case of a 5-year-old boy with primary
isolated endobronchial ALCL.
1. Case report
A ‘healthy’ asymptomatic 5-year-old boy was discovered, on
routine physical examination, to have absent breath sounds over his
right hemithorax.
On chest X-ray there was a complete white-out of the right
hemithorax with a shift of the mediastinum toward the side of the
opaciﬁcation (Fig. 1A). A chest CT scan revealed the presence of a
mass obstructing the right mainstem bronchus with occlusion and
surrounding edema (Fig. 1B). Bronchoscopy revealed a soft white
ﬂeshy tumor arising from the lumen of the right upper lobe
bronchus that was biopsied (Fig. 1C).license.
Fig. 1. A) Plain radiograph of the chest reveals complete whiteout of the right hemithorax. B) Computed tomography (CT) scan identiﬁes a mass in the right mainstem bronchus with
occlusion and surrounding edema. C) Bronchoscopy image shows the presence of an obstructive mass lesion within the right mainstem bronchus (black arrow).
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of uniform neoplastic “small blue cells” with no characteristic
growth pattern was identiﬁed (Fig. 2A and B). Tumor cells were
strongly positive to CD99 (Fig. 2C) with a Ki67 labeling index
estimated at 90%. Tumor cells were negative for S100, CD3, CD20,
CD79a, MPO, TDT, PLAP, LMKT, AFP, Synaptophysin, chromogranin,
TTF-1, CK7, CD1a, myogenin, pan-keratin, WT-1, and HCG (Fig. 2D).
The pathological diagnosis was a neoplasm with an immunophe-
notype consistent with Ewing’s sarcoma/primitive neuro-
ectodermal tumor (PNET).
A week later the bronchoscopy was repeated to plan for oper-
ative resection of the tumor (right upper lobectomy  sleeve
resection of the bronchus intermedius) and additional tumor
debulking was performed with the tissue being sent for patho-
logical evaluation. Histopathology of this tissue showed uniform
polygonal dark blue cells with ﬁne granular chromatin and scant-
to-moderate amounts of eosinophilic cytoplasm (Fig. 2E and F).
Lesional cells were strongly positive to CD45, with some expres-
sion of CD99, which was inconsistent with the previous reportedFig. 2. AeD) Histopathological evaluation of the ﬁrst biopsy sample from the right mainst
shows sheets of uniform small “blue cells.” B) Photomicrograph of hematoxylin & eosin stain
of immunohistochemically stained slide at medium power shows strong expression for CD99
no expression of S100, CD3, CD20, CD79A, MPO, TDT, PLAP, LMKT, AFP, Synaptophysin, CGA,
the second biopsy sample obtained at debulking of the tumor with re-biopsy. E) Photomicro
dark blue cells with ﬁne granular chromatin, inconspicuous nucleoli and scant cytoplasm. F
dense hyperchromatic cells with increased mitoses and apoptosis. G) Photomicrograph of im
CD30. H) Photomicrograph of immunohistochemically stained slide at medium power show
in this ﬁgure legend, the reader is referred to the web version of this article.)diagnosis of Ewing’s sarcoma. Additionally, the cells were strongly
positive to CD30 (Fig. 2G), ALK-1 (Fig. 2H), EMA, TIA-1, and
Granzyme. Moderate expression of KP1CD68 was noted, and cells
were negative for CD10, CD4, CD8, CD1a, TDT, CD117, and CD34.
This immunophenotype favored the diagnosis of anaplastic large
cell lymphoma (ALCL). External pathological review of the biopsy
material conﬁrmed this suspicion, and the patient was diagnosed
with ALCL ALKþ null phenotype. FISH for ALK translocation
revealed an abnormal pattern in 54% with evidence of aneuploidy
and clonal evolution.
A detailed staging work-up including complete blood count,
bone marrow, CSF, plain X-rays ultrasonography, CT, MRI, and
skeletal scintigraphy was undertaken. There were no B-symptoms
and no extrathoracic involvement was detected. It was therefore
determined that this lesion was isolated to the right upper lobe of
the lung.
The patient was started on chemotherapy in accordance with
the Children’s Oncology Group protocol including intrathecal
methotrexate, IV vincristine, IV doxorubicin, and PO prednisone. Atem bronchus. A) Photomicrograph of hematoxylin & eosin stained slide at low power
ed slide at medium power shows no characteristic growth pattern. C) Photomicrograph
. D) Photomicrograph of immunohistochemically stained slide at medium power shows
TTF1, CK7, Myogenin, pankeratin, WT1, and HCG. EeH) Histopathological evaluation of
graph of hematoxylin & eosin stained slide at medium power shows uniform polygonal
) Photomicrograph of hematoxylin & eosin stained slide at high power shows abnormal
munohistochemically stained slide at medium power shows strong positive staining to
s strong expression with ALK-1 antibodies. (For interpretation of the references to color
R. Kanthan et al. / J Ped Surg Case Reports 2 (2014) 66e6968eight months follow-up there was no clinical, pathological, or
radiographic evidence of residual disease.
2. Discussion
Endobronchial tumors are rare in children, accounting for only
0.2% of all pediatric malignancies [4]. As such, these are often
missed in the differential diagnosis of persistent abnormalities of
chest radiographs; therefore, increased awareness is necessary
for accurate identiﬁcation [5]. Benign endobronchial tumors
include hamartoma, hemangioma, papilloma, plasma cell gran-
ulomas, leiomyomas, and mucus gland tumor; malignant tumors
include bronchial adenoma, carcinoids, mucoepidermoid carci-
noma, and adenoid cystic carcinoma [4]. Though rare, the most
common primary bronchial tumor in childhood is carcinoid tu-
mor, as opposed to adults wherein squamous cell carcinomas
predominate [4e6]. The second most frequent tumor of the
endobronchium in the ﬁrst two decades of life is mucoepi-
dermoid carcinoma, the malignant potential of which is contro-
versial [6]. In addition to tumors, others bronchial pathologies
must be excluded such as bronchial stenosis, or extrinsic
compression due to lymphadenopathy, tuberculosis, or sarcoid-
osis [7]. Particularly in pediatrics, aspiration of foreign bodies,
asthma with mucus plugging, or granulomatous infection should
also be considered [5]. Lymphoma rarely presents as an endo-
bronchial lesion. The endobronchial lesion in non-Hodgkin’s
lymphoma is a rare intrathoracic manifestation and is usually
discovered in the background of advanced widely disseminated
disease [6]. However, accurate early histological diagnosis is
imperative for successful management of such lesions.Table 1
Pediatric endobronchial primary anaplastic large cell lymphoma.
NS, not speciﬁed.
This table annotates in chronological order all cases of pediatric endobronchial ALCL res
lighted’ cases are those that were isolated to the endobronchium with no evidence of exALCL was ﬁrst recognized in 1982 when the monoclonal
antibody Ki-1 was discovered within the Hodgkin’s disease cell
line. This antibody was subsequently identiﬁed as an activation
antigen expression on T-cells, B-cells and activated histiocytes,
and was assigned to the CD30 cluster. Three years later, in 1985,
Stein et al. identiﬁed expression of this antigen in large cell lym-
phomas with prominent sinusoidal invasion. It was then proposed
that these CD30 positive tumors represent a distinct clinicopath-
ological entity. In 1988 Kiel classiﬁed these neoplasms as “large
cell anaplastic lymphoma” in which the term ‘anaplastic’ refers to
the abnormal growth of neoplastic cells that do not resemble
normal lymphoid cells [8]. Since this initial identiﬁcation, the
genetic and molecular etiology of ALCL has been further eluci-
dated. In the majority of ALCLs (>80e85%), a t(2;5)(p23;q35)
chromosomal translocation fuses nucleophosmin (NPM) on
chromosome 5 with anaplastic lymphoma kinase (ALK) on chro-
mosome 2 [2]. NPM-ALK plays a role in the aberrant phosphory-
lation of intracellular substrates resulting in lymphomagenesis. As
such, staining for ALK is a speciﬁc diagnostic tool and is positive in
over 80% of cases [8]. However, ALK dysregulation is not unique to
ALCL. ALK alterations have also been reported in many other tu-
mors including inﬂammatory myoﬁbroblastic tumors, which can
also present as an incidental/obstructive endobronchial mass and,
though rare, remains a clinically important and pathologically
distinct lesion of the respiratory tract in children [9].
ALCL in children is most common at the age of 10e11 years, and
is six times more common in males [8]. The most common pre-
sentation is with lymphadenopathy; however, precise clinical
signs and symptoms depend on the anatomical location of the
involved lymph nodes. Fever, bony lesions, spleen/skin inﬁltration,tricted to the English language as available on PubMed and Medline. Purple ‘high-
trapulmonary involvement [2,3,13].
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other presenting symptoms [10]. Children with ALCL may have an
indolent phase characterized by mild lymphadenopathy with fe-
ver prior to progression. Endobronchial ALCL typically presents
with dyspnea and atelectasis of the distal parenchyma [11]. Plastic
bronchitis caused by neoplastic inﬁltrates originating from an
ALCL has also been reported in a seven-year-old girl under
investigation for refractory pneumonia [12]. Over half of all ALCL
patients present with stage III/IV and have systemic symptoms.
Extranodal disease is present in 40e50% of cases [2]. The pre-
sentation of NHLs as endobronchial neoplasms is extremely rare.
On immunohistochemical (IHC) staining, ALCL cells are positive
for CD30, CD45, EMA, and BNH9. Expression of T-cell antigens
including CD2 and CD4 is common, with CD43 expression in 2/3 of
cases [13]. The T-cell markers CD3 and CD45ROmay be negative in
>50% of cases [8]. Thus, the use of limited immunohistochemical
panels can potentially lead to confusion of ALCL with other neo-
plasms as seen in our index case. Additionally, approximately
70e80% of ALKþ ALCLs express CD99, an antigen also present in
Ewing’s sarcoma. Further, as ALCLs can be of the null phenotype
with no expression of routine T- and B-cell markers, this remains a
common diagnostic pitfall for “Ewing’s sarcoma” as seen in our
case and can only be averted by a high index of clinical and
pathological suspicion [14]. Such distinction is extremely impor-
tant as the primary treatment of a malignant endobronchial tumor
is surgical whereas in lymphoma, chemotherapy remains the gold
standard.
ALCL in children responds well to chemotherapy, with the
majority entering complete remission. However, recurrence rates
may be as high as 39e81% and predominantly occur within
months of treatment completion [3]. The 5-year survival rate is
79.8% for ALK positive disease, and 32.9% for ALK negative disease
[11]. ALK-positive ALCL tumors have a higher frequency of extra-
nodal involvement than ALK-negative tumors [15]. The most sig-
niﬁcant prognostic factor for children with ALCL is ALK positivity,
which is associated with a good therapeutic response and longer
overall survival [16].
While pulmonary involvement of ALCL occurs as a result of
dissemination in 12% of all cases, primary endobronchial ALCL is
extremely rare [1]. The ﬁrst case of endobronchial ALCL without
disseminated disease was described by Guerra et al. in 2006 [3].
Due to the rarity of these lesions, guidelines for management are
largely consensus-based rather than evidence-based and the
optimal therapy still remains to be determined.
Reviews of large series of CD30þ ALCL in 225 [17], 82 [18], and
32 [19] children revealed no reported cases of isolated endo-
bronchial ALCL. Though NHL presenting as an endobronchial tu-
mor has been reported in the adult population, to the best of our
knowledge, only three case reports have described primary, iso-
lated endobronchial ALCL in the pediatric English literature
[2,3,13]. These patients were aged 9 (female), 13 (female), and 17
(female). Our case is therefore the ﬁrst report of a male with this
diagnosis, as well is the youngest patient. Table 1 is a compre-
hensive list of pediatric endobronchial ALCLs as reported in the
English literature [2,3,11,13,20,21].
3. Conclusion
On clinical grounds, ALCL is a relatively infrequent tumor.
Endobronchial lesions in NHL are the rarest intrathoracic mani-
festation of ALCL even in advanced widely disseminated disease. Inthis context, this case of isolated endobronchial presentation of
ALCL remains a rarity and an exceedingly uncommon event. Though
histopathology is the primary tool to differentiate ALCL from other
benign and malignant endobronchial lesions, it is important to be
aware of the diagnostic pitfall of the ‘null phenotype’ ALCL, which is
negative to routine T- and B-cell markers. In summary, such lesions,
due to their rarity and complexity remain diagnostic challenges
that necessitate a high degree of clinical suspicion for accurate
identiﬁcation to guide early appropriate treatment.
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